Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study ...
Got To Article
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose.